Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a)

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 6, 1999, Pages 2028-2033

  Svensson, Johan ^a   Jansson, J O ^a   Ottosson, M ^b   Johannsson, G ^a   Taskinen, M R ^c   Wiklund, O ^b   Bengtsson, B A ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IBUTAMOREN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033304520     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.6.2028     Document Type: Article

References (61)

1. Growth hormone-releasing hormone
2. On the actions of the growth hormone-releasing hexapeptide, GHRP-6
3. Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release
4. A non-peptidyl growth hormone secretagogue
5. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles
6. Stimulation of the growth hormone (GH)-insulin-like growth factor-I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects
7. A pituitary gland and hypothalamic receptor that functions in growth hormone release
8. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man
9. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
10. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure
11. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors
12. 100 synthesis and secretion in the rat liver
13. Continuous but not intermittent administration of growth hormone to hypophysectomized increases apolipoprotein-E secretion from cultured hepatocytes
14. Stimulation of in vitro triglyceride synthesis in the rat hepatocyte by growth hormone treatment in vivo
15. In vivo growth hormone treatment stimulates secretion of very low density lipoproteins by the perfused rat liver
16. Two weeks of daily injections and continuous infusion of recombinant growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity
17. Differential impact of age, sex steroid hormones, and obesity on basal vs. pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay
18. Pathophysiology of insulin resistance in human disease
19. Visceral obesity: A 'civilization syndrome'
20. Clinical aspects of growth hormone deficiency in adults
21. Cardiovascular risk factors in adult patients with growth hormone deficiency
22. Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy
23. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations
24. The effects of short and long term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance
25. Low dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low density lipoprotein cholesterol concentrations in middle-aged men
26. GH treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure
27. Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men
28. The mysteries of lipoprotein(a)
29. Lipoprotein(a)
30. Lipoprotein(a). A genetic risk factor for premature coronary heart disease
31. Increased lipoprotein(a) concentrations after growth hormone (GH) treatment in patients with isolated GH deficiency
32. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults; influence of gender and apo(a) and apoE phenotypes
33. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivy, and cardiovascular risk factors in hypopituitary adults
34. An open 36-month study of lipid changes with growth hormone in adults: Lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency
35. Increased concentrations of serum lipoprotein (a) in response to growth hormone treatment
36. Alphalipoprotein cholesterol in relation to acute myocardial infarction and its risk factors
37. Estimation of low-density lipoprotein in plasma, without use of the preparative ultracentrifuge
38. Serum lipids and apolipoprotein levels in women with acute myocardial infarction
39. Nondenaturing polyacrylamide gradient gel electrophoresis
40. Elecrophoresis in polyacrylamide concentration gradient
41. Lipoprotein analysis - A practical approach
42. Microdetermination of long-chain fatty acids in plasma and tissues
43. The effect of growth hormone replacement of serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients
44. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults
45. Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults
46. Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy
47. LDL subclasses in IDDM patients: Relation to diabetic nephropathy
48. Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: Importance of serum triglycerides
49. Beneficial average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes
50. Effects of growth hormone deficiency and therapy in adults on skeletal muscle glucose metabolism, lipid profiles and regional body composition
51. LDL subfractions in acromegaly: Relation to growth hormone and insulin-like growth factor-I
52. Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contibute to the dyslipidaemia of adult growth hormone deficiency
53. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency
54. Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: Gender-specific metabolic effects
55. Dyslipidemia in non-insulin-dependent diabetes mellitus
56. Effects of a 7-day treatment with a novel, orally active growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor-I, and adenocortical function in normal young men
57. Direct effects of corticotropin on plasma lipoprotein metabolism in man-studies in vivo and in vitro
58. Growth hormone treatment of obese women for 5 wk; effect on body composition and adipose tissue LPL activity
59. Decline of postheparin plasma lipoprotein lipase in acromegalic patients
60. The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients